glp-1 receptor agonists cardiovascular benefits Effects of Glucagon-Like Peptide-1 The Cardiovascular Physiology of Glucagon-like

Polyethylene glycol (PEG) is a water-soluble inert polymer that reduces the renal clearance of the drug and prolongs the half-life, in addition to enhancing water solubility and preventing proteolysis

These same members lost on average 11.7 percent of body weight after enrollment, a 13x increase in total weight loss

GLP-1 receptor agonists are transforming obesity treatment

Sleep Disorders Obstructive sleep apnea (OSA) represents a significant clinical breakthrough for GLP-1 RAs in sleep medicine, culminating in the historic FDA approval of tirzepatide (Zepbound) on December 20, 2024, as the first medication specifically indicated for moderate-to-severe OSA in adults with obesity [154]

Eur J Heart Fail (2017) 19(1):6977

Ozempic, a popular brand of a GLP-1 agonist drug, has had multiple lawsuits filed against its manufacturer, Novo Nordisk, for the adverse effects that patients experienced with long-term use